KLOW is GLOW plus KPV: an 80 mg vial of 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV.
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
KLOW is 4 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
GHK-Cu50 mg per vial
BPC-15710 mg per vial
TB-500 / TB-410 mg per vial
KPV10 mg per vial
What published studies and recent community write-ups report about amounts, timing and course length. 1 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Preclinical1 row | |||||
| Related two-peptide combination in rats: BPC-157 plus TB-500 after Achilles tendon repair (not the KLOW product)32 male Sprague-Dawley rats, 8 per group, after Achilles tendon transection and repair | BPC-157 10 mcg/kg per day; TB-500 60 mcg/kg per day; both together in the combination group | Once daily | Intraperitoneal | 4 weeks after surgeryNot applicable | Joint Diseases and Related Surgery (PubMed)2026 |
| TB-500 alone significantly raised load to failure and improved histology, BPC-157 alone improved scores without significance, and giving both together added nothing over either agent alone. The study had no GHK-Cu or KPV arm, so it tests half of KLOW; it is the only published animal work on any pair of these peptides found for this page, and it argues against the synergy that blend marketing assumes. | |||||
| Community-reported3 rows | |||||
| Community dosing chart: 80 mg vial in 3 mL, daily draw stepped up over 12 weeks | 2,667 mcg of blend (10 units, 0.10 mL) in weeks 1-2, 4,000 mcg (15 units) in weeks 3-6 and 5,333 mcg (20 units) in weeks 7-12, at 26.67 mg/mL; the 10-unit draw holds about 1,667 mcg GHK-Cu and 333 mcg each of BPC-157, TB-500 and KPV | Once daily | Subcutaneous, U-100 insulin syringe | 8-12 weeks, with some schedules extended to about 16Not stated on this page | Community resource2025 |
| At 3 mL one unit holds about 267 mcg of blend and a vial lasts 15-30 days depending on the step, so the chart tells readers to plan more than one vial. It also answers the 2 mg GHK-Cu question: a 12-unit (0.12 mL) draw delivers 2 mg GHK-Cu and 400 mcg each of the other three, 3.2 mg of blend in total. The page says the figures come from how the fixed-ratio vial reconstitutes, not from any approved dosing, and that no cycle length has been established because the combination has never been studied clinically; it closes with a vendor recommendation. | |||||
| Community schedule: fixed 10-unit draw with a frequency taper, then a break | 10 units (0.10 mL), about 2,667 mcg of blend: 1,667 mcg GHK-Cu and 333 mcg each of BPC-157, TB-500 and KPV, from 80 mg in 3 mL | Daily in weeks 1-4 (activation), five times a week in weeks 5-8 (consolidation), then 2-3 times a week (maintenance) | Subcutaneous, rotating abdomen, flank and thigh | 8-12 weeks on (4 weeks daily, 4 weeks at five a week, 2-4 weeks of maintenance)4-8 weeks off before repeating | Community resource2026 |
| The same site's longer guide holds the draw at 10 units and changes only the frequency, which it calls a fading frequency pattern over a flat dose line. It counts about 54-60 doses for a full cycle, roughly two 30-dose vials, and advises opening the second only when the first runs out because each opened vial has a finite in-use window. It states that there is no registered human trial of the blend, that reported side effects (injection-site redness, flushing, transient taste changes) come from component research and user reports, and that the 62.5% GHK-Cu share is why the blend is anchored to that peptide. | |||||
| Community protocol page: reconstitution table and what a 5-unit draw contains | 5 units (0.05 mL) delivers 1.25 mg GHK-Cu and 250 mcg each of BPC-157, TB-500 and KPV at 2 mL (40 mg/mL); 2.5 mg and 500 mcg each at 1 mL; 625 mcg and 125 mcg each at 4 mL | Not stated | Subcutaneous with a U-100 insulin syringe | Use within the bacteriostatic water's preservative window once reconstitutedNot described | Community resource2026 |
| One community guide presents these as arithmetic examples rather than recommendations and says plainly that no validated human dose exists for the blend. Its advice is to anchor the draw to whichever component is being studied, most often GHK-Cu at 62.5% of the vial, and to accept that the other three scale with it. It expects a faint blue tint after reconstitution, lists the component literature it relies on (none of it on the blend), and notes that BPC-157 and TB-500 are WADA-prohibited. | |||||
The published schedules start with one 10-unit draw a day from an 80 mg vial made up in 3 mL (about 2.67 mg of blend). One 30-dose vial covers this phase; the stepped chart instead begins at 10 units for two weeks and moves to 15 units in week 3.
Community accounts place digestive comfort and subjective joint or soft-tissue relief here, attributed to KPV and BPC-157. One community guide rates these the least reliable reports because pain fluctuates and people start a protocol when something is flaring.
The frequency drops to five draws a week at the same 10 units. Skin texture and tone changes are the reports that cluster in weeks 4-8, the one window whose timing matches an established process, dermal collagen turnover.
Two to three draws a week, then a break of 4-8 weeks. Eight to twelve weeks is described as the window most protocols run before pausing; one community guide calls that convention, not evidence, and no trial has tracked anyone on KLOW.
Plus 8 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
What sources report for each peptide on its own. In KLOW the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
KLOW is GLOW plus KPV: an 80 mg vial of 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV. The name is a vendor and community label; the vendor and many other research-chemical sellers list this 5:1:1:1 vial for skin quality, connective-tissue recovery and inflammation, and a reference site describes it as a vendor-assembled combination whose ratio is set by each seller rather than by any standard. No study at any level has tested the four peptides together: the component pages hold the only evidence, a 2026 rat study that gave BPC-157 and TB-500 together found no additive effect, and every protocol below is a vendor or community account of how the 80 mg vial is mixed and drawn.
This educational summary has not yet been independently source-verified and should not be treated as an established finding.
A four-peptide research blend discussed in tissue remodeling and inflammation contexts
Commonly described component list and amounts for KLOW-style formulations
Copper-binding tripeptide studied in connective tissue and skin remodeling contexts
α-MSH - derived tripeptide motif studied for anti-inflammatory and immunomodulatory effects
Peptide associated with actin dynamics, cell migration, and angiogenesis-related biology
Gastric pentadecapeptide with extensive preclinical literature in protection and repair models
Each number is the vial amount for that component. It is not a per-draw amount.
Technical fields and limitations remain subject to source verification.
5 curated references, each with its journal, year and study model, plus 8 community resources reported but not linked.